Senseonics Holdings, Inc. SENS
We are a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring ("CGM") system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Our implantable CGM system ("Eversense"), including Eversense E3 and Eversense 365 CGM systems are designed to continually and accurately measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to twelve months in the case of Eversense 365 and six months in the case of Eversense E3, as compared to seven to 15 days for non-implantable CGM systems. In September 2024, the 365-day extended life Eversense E3 CGM system was approved by the FDA and, through Ascensia Diabetes Care Holdings AG ("Ascensia"), we began commercializing Eversense 365 in the fourth quarter of 2024. In January 2026, we took over full commercial responsibility for Eversense 365 in the United States and began marketing and distributing the product with our own sales force. In June 2022, we affixed the CE Mark to the Eversense E3 CGM system and Ascensia began commercialization in select markets in Europe during the third quarter of 2022. In January 2026, the Company obtained CE Mark approval for Eversense 365 and expects to launch Eversense 365 in the European Territories by the second half of 2026.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.3M | $22.5M | $22.4M | $16.4M | $1.4M | $1.4M | $4.9M | $2.0M | $529.0K | $332.0K |
| Cost of revenue | $19.5M | $21.9M | $19.3M | $13.7M | $14.5M | $22.3M | $40.7M | $27.1M | $9.8M | $660.0K |
| Gross profit | $15.8M | $533.0K | $3.1M | $2.7M | -$811.0K | -$17.4M | -$19.4M | -$8.1M | -$3.4M | -$328.0K |
| R&D | $31.6M | $41.1M | $48.8M | $39.7M | $27.2M | $20.4M | $38.4M | $31.9M | $30.7M | $26.3M |
| SG&A | $52.5M | $34.2M | $29.9M | $31.6M | $29.2M | $41.4M | $23.2M | $19.8M | $15.3M | $13.0M |
| Operating income | -$68.3M | -$74.8M | -$75.6M | -$68.6M | -$57.2M | -$79.1M | -$130.7M | -$87.6M | -$56.3M | -$42.4M |
| Interest expense | $5.0M | $8.4M | $11.1M | $18.7M | $16.7M | $16.2M | $11.8M | $8.3M | $3.1M | $1.6M |
| Pre-tax income | -$69.1M | -$78.6M | -$60.4M | $142.1M | -$302.5M | -$175.2M | — | -$94.0M | -$59.1M | -$43.9M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | — | $0 | $0 | $0 |
| Net income | -$69.1M | -$78.6M | -$60.4M | $142.1M | -$302.5M | -$175.2M | -$115.5M | -$94.0M | -$59.1M | -$43.9M |
| EPS, basic | -1.66 | -2.50 | -0.11 | 0.30 | -0.72 | -0.77 | -0.61 | — | — | — |
| EPS, diluted | -1.66 | -2.50 | -0.11 | -0.11 | -0.72 | -0.77 | -0.61 | -0.60 | -0.51 | -0.49 |
| Shares, diluted (wtd. avg.) | 41.7M | 31.5M | 568.0M | 618.2M | 422.3M | 227.9M | 188.8M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $40.2M | $74.6M | $75.7M | $35.8M | $33.5M | $18.2M | $95.9M | $136.8M | $16.1M | $13.0M |
| Short-term investments | $53.8M | $0 | $33.7M | $108.2M | $96.4M | — | — | $0 | $20.3M | $7.3M |
| Inventory | $6.7M | $4.4M | $8.8M | $7.3M | $6.3M | $5.3M | $16.9M | $10.2M | $3.0M | $477.0K |
| Total current assets | $117.5M | $91.4M | $130.0M | $161.2M | $144.4M | $30.2M | $127.8M | $158.1M | $44.9M | $21.4M |
| Property, plant and equipment | — | — | $1.2M | $1.1M | $1.3M | $1.6M | $2.0M | $1.8M | $853.0K | $735.0K |
| Other intangibles | $600.0K | — | — | — | — | — | — | — | — | — |
| Total assets | $126.3M | $100.4M | $138.2M | $177.7M | $198.9M | $35.9M | $132.8M | $160.0M | $45.9M | $22.3M |
| Accounts payable | $4.1M | $3.2M | $4.6M | $419.0K | $1.2M | $1.8M | $4.3M | $4.4M | $7.7M | $3.1M |
| Total current liabilities | $24.3M | $38.8M | $17.3M | $31.5M | $18.4M | $16.6M | $126.7M | $28.9M | $23.1M | $11.6M |
| Long-term debt | $35.6M | $34.7M | $41.2M | $56.4M | $59.8M | $57.2M | $11.8M | — | — | — |
| Total liabilities | $65.2M | $79.3M | $64.8M | $142.6M | $384.5M | $177.2M | $141.4M | $88.7M | $38.7M | $27.1M |
| Retained earnings | -$1.02B | -$947.9M | -$869.3M | -$808.9M | -$951.0M | -$648.5M | -$473.3M | -$357.8M | -$263.8M | -$204.7M |
| Total equity | $61.0M | -$16.6M | $35.8M | -$2.6M | -$185.5M | -$144.1M | -$8.6M | $71.3M | $7.3M | -$4.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$59.1M | -$60.5M | -$70.2M | -$66.3M | -$56.1M | -$67.4M | -$136.0M | -$90.8M | -$55.7M | -$38.0M |
| Depreciation and amortisation | $1.5M | $1.5M | $1.3M | $985.0K | $1.2M | $1.1M | $1.0M | $270.0K | $227.0K | $155.0K |
| Stock-based compensation | $10.2M | $9.2M | $8.7M | $8.6M | $9.0M | $7.3M | $8.1M | $6.4M | $4.0M | $2.4M |
| Capital expenditure | $1.1M | $2.2M | $350.0K | $312.0K | $210.0K | $181.0K | $1.0M | $989.0K | $345.0K | $479.0K |
| Investing cash flow | -$53.4M | $32.8M | $89.7M | $26.9M | -$148.7M | -$181.0K | -$1.0M | $19.4M | -$13.2M | -$7.8M |
| Financing cash flow | $78.2M | $26.8M | $20.4M | $41.8M | $220.1M | -$10.1M | $96.2M | $192.0M | $72.1M | $54.9M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-041541.
Plot the figures US dollars
- Accounts payable
- Total current liabilities
- Inventory
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Accounts payable | $3.1M | $7.7M | $4.4M | $4.3M | $1.8M | $1.2M | $419.0K | $4.6M | $3.2M | $4.1M |
| Total current liabilities | $11.6M | $23.1M | $28.9M | $126.7M | $16.6M | $18.4M | $31.5M | $17.3M | $38.8M | $24.3M |
| Inventory | $477.0K | $3.0M | $10.2M | $16.9M | $5.3M | $6.3M | $7.3M | $8.8M | $4.4M | $6.7M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Material agreement signed Item 1.01
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3823
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DHR | DANAHER CORP /DE/ | $145.98B | 41.1x | 2.9% |
| KEYS | Keysight Technologies, Inc. | $55.71B | 66.6x | 8.0% |
| AME | AMETEK INC/ | $54.50B | 37.1x | 6.6% |
| ROP | ROPER TECHNOLOGIES INC | $40.28B | 28.7x | 12.3% |
| MKSI | MKS INC | $17.60B | 59.6x | 9.6% |
| FTV | Fortive Corp | $17.36B | 32.9x | 1.9% |
| CGNX | COGNEX CORP | $10.47B | 91.5x | 8.7% |
| RAL | Ralliant Corp | $7.02B | — | -4.0% |